Increased interleukin-1β levels following low dose MDMA induces tolerance against the 5-HT neurotoxicity produced by challenge MDMA

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Mayado, Andrea ^a   Torres, Elisa ^a   Gutierrez Lopez, Maria D ^a   Colado, Maria I ^a   O'Shea, Esther ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

5 HT; Il 1 ; Il 1ra; MDMA; Neurotoxicity; Preconditioning; Sil 1Ri; Tolerance

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; SEROTONIN TRANSPORTER; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FRONTAL CORTEX; HYPERTHERMIA; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SEROTONIN UPTAKE; TOXICITY TESTING; ANIMAL; BODY TEMPERATURE; BRAIN; DRUG EFFECT; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; PHYSIOLOGY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BODY TEMPERATURE; BRAIN; DRUG TOLERANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 82055181841     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-165     Document Type: Article

References (51)

1. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 2003, 55:463-508. 10.1124/pr.55.3.3, 12869661.
2. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987, 241:338-345.
3. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 1988, 8:2788-2803.
4. Colado MI, O'Shea E, Granados R, Murray TK, Green AR. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 1997, 121:889-900. 10.1038/sj.bjp.0701213, 1564770, 9222545.
5. O'Shea E, Granados R, Esteban B, Colado MI, Green AR. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 1998, 37:919-926. 10.1016/S0028-3908(98)00029-X, 9776387.
6. Hewitt KE, Green AR. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats. Neuropharmacology 1994, 33:1589-1595. 10.1016/0028-3908(94)90134-1, 7539115.
7. Sharkey J, McBean DE, Kelly PA. Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy"). Psychopharmacology (Berl) 1991, 105:113-118.
8. O'Shea E, Orio L, Escobedo I, Sanchez V, Camarero J, Green AR, Colado MI. MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature. Br J Pharmacol 2006, 148:778-785. 1617070, 16770327.
9. Orio L, O'Shea E, Sanchez V, Pradillo JM, Escobedo I, Camarero J, Moro MA, Green AR, Colado MI. 3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem 2004, 89:1445-1453. 10.1111/j.1471-4159.2004.02443.x, 15189347.
10. O'Shea E, Sanchez V, Orio L, Escobedo I, Green AR, Colado MI. 3,4-Methylenedioxymethamphetamine increases pro-interleukin-1beta production and caspase-1 protease activity in frontal cortex, but not in hypothalamus, of Dark Agouti rats: role of interleukin-1beta in neurotoxicity. Neuroscience 2005, 135:1095-1105. 10.1016/j.neuroscience.2005.06.084, 16165281.
11. Janoff A. Alterations in lysosomes (intracellular enzymes) during shock; effects of preconditioning (tolerance) and protective drugs. Int Anesthesiol Clin 1964, 2:251-269. 10.1097/00004311-196402000-00008, 14125012.
12. Barone FC, White RF, Spera PA, Ellison J, Currie RW, Wang X, Feuerstein GZ. Ischemic preconditioning and brain tolerance: temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression. Stroke 1998, 29:1937-1950. 10.1161/01.STR.29.9.1937, 9731622.
13. Escobedo I, Peraile I, Orio L, Colado MI, O'Shea E. Evidence for a role of Hsp70 in the neuroprotection induced by heat shock pre-treatment against 3,4-methylenedioxymethamphetamine toxicity in rat brain. J Neurochem 2007, 101:1272-1283. 10.1111/j.1471-4159.2007.04459.x, 17328712.
14. Kitagawa K, Matsumoto M, Kuwabara K, Tagaya M, Ohtsuki T, Hata R, Ueda H, Handa N, Kimura K, Kamada T. 'Ischemic tolerance' phenomenon detected in various brain regions. Brain Res 1991, 561:203-211. 10.1016/0006-8993(91)91596-S, 1802339.
15. Omata N, Murata T, Takamatsu S, Maruoka N, Yonekura Y, Fujibayashi Y, Wada Y. Region-specific induction of hypoxic tolerance by expression of stress proteins and antioxidant enzymes. Neurol Sci 2006, 27:74-77. 10.1007/s10072-006-0570-6, 16688605.
16. Wang CH, Chang A, Tsai MJ, Cheng H, Liao LP, Lin AM. Kainic acid-induced oxidative injury is attenuated by hypoxic preconditioning. Ann N Y Acad Sci 2005, 1042:314-324. 10.1196/annals.1338.054, 15965077.
17. Obrenovitch TP. Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol Rev 2008, 88:211-247. 10.1152/physrev.00039.2006, 18195087.
18. Lastres-Becker I, Cartmell T, Molina-Holgado F. Endotoxin preconditioning protects neurones from in vitro ischemia: role of endogenous IL-1beta and TNF-alpha. J Neuroimmunol 2006, 173:108-116. 10.1016/j.jneuroim.2005.12.006, 16439029.
19. Shin JA, Park EM, Choi JS, Seo SM, Kang JL, Lee KE, Cho S. Ischemic preconditioning-induced neuroprotection is associated with differential expression of IL-1beta and IL-1 receptor antagonist in the ischemic cortex. J Neuroimmunol 2009, 217:14-19. 10.1016/j.jneuroim.2009.06.001, 2916648, 19545912.
20. Bhide NS, Lipton JW, Cunningham JI, Yamamoto BK, Gudelsky GA. Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain. Brain Res 2009, 1286:32-41. 2754382, 19555677.
21. Mayado A, Torres E, Peraile I, Izco M, Gutierrez-Lopez MD, Colado MI, O'Shea E. Repeated low dose MDMA protects against a subsequent neurotoxic dose of MDMA and reduces IL-1β release [abstract]. Fundamental & Clinical Pharmacology 2008, 22(S2):P139.
22. Murakami N, Sakata Y, Watanabe T. Central actions sites of interleukin-1 beta for inducing fever in rabbits. J Physiol 1990, 428:299-312. 1181648, 2231415.
23. Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J Exp Med 1972, 136:128-142. 10.1084/jem.136.1.128, 2139184, 5033417.
24. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin-1 receptor complex. J Biol Chem 1995, 270:13757-13765. 10.1074/jbc.270.23.13757, 7775431.
25. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev 1997, 8:253-265. 10.1016/S1359-6101(97)00023-3, 9620641.
26. Colado MI, O'Shea E, Granados R, Esteban B, Martín AB, Green AR. Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration. Br J Pharmacol 1999, 126:911-924. 10.1038/sj.bjp.0702373, 1571217, 10193771.
27. König JFR, Klippel RA. The Rat Brain. A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem 1963, New York, Robert E Krieger Publishing Co. Inc.
28. Baldwin HA, Williams JL, Snares M, Ferreira T, Cross AJ, Green AR. Attenuation by chlormethiazole administration of the rise in extracellular amino acids following focal ischaemia in the cerebral cortex of the rat. Br J Pharmacol 1994, 112:188-194. 1910275, 8032640.
29. Wang X, Baumann MH, Xu H, Morales M, Rothman RB. (+/-)-3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. J Pharmacol Exp Ther 2005, 314:1002-1012. 10.1124/jpet.105.088476, 15937150.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
32. Torres E, Gutierrez-Lopez MD, Borcel E, Peraile I, Mayado A, O'Shea E, Colado MI. Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain. J Neurochem 2010, 113:67-78. 10.1111/j.1471-4159.2010.06578.x, 20067581.
33. Torres E, Gutierrez-Lopez MD, Mayado A, Rubio A, O'Shea E, Colado MI. Changes in interleukin-1 signal modulators induced by 3,4-methylenedioxymethamphetamine (MDMA): regulation by CB2 receptors and implications for neurotoxicity. J Neuroinflammation 2011, 8:53. 10.1186/1742-2094-8-53, 3113340, 21595923.
34. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 2003, 26:248-254. 10.1016/S0166-2236(03)00071-7, 12744841.
35. Piper BJ, Vu HL, Safain MG, Oliver AJ, Meyer JS. Repeated adolescent 3,4-methylenedioxymethamphetamine (MDMA) exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist. J Pharmacol Exp Ther 2006, 317:838-849. 10.1124/jpet.105.095760, 16434566.
36. Piper BJ, Ali SF, Daniels LG, Meyer JS. Repeated intermittent methylenedioxymethamphetamine exposure protects against the behavioral and neurotoxic, but not hyperthermic, effects of an MDMA binge in adult rats. Synapse 2010, 64:421-431. 10.1002/syn.20744, 20169574.
37. Green AR, O'Shea E, Colado MI. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol 2004, 500:3-13. 10.1016/j.ejphar.2004.07.006, 15464016.
38. Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI, Green AR. Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. J Psychopharmacol 2004, 18:412-416. 10.1177/026988110401800312, 15358986.
39. Orio L, Llopis N, Torres E, Izco M, O'Shea E, Colado MI. A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons. Neurotox Res 2010, 18:187-99. 10.1007/s12640-009-9120-3, 19777321.
40. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991, 12:404-410. 10.1016/0167-5699(91)90142-G, 1838480.
41. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001, 2:734-744. 10.1038/35094583, 11584311.
42. Martin D, Chinookoswong N, Miller G. The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp Neurol 1995, 130:362-367.
43. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992, 29:243-246. 10.1016/0361-9230(92)90033-T, 1388088.
44. Stroemer RP, Rothwell NJ. Cortical protection by localized striatal injection of IL-1ra following cerebral ischemia in the rat. J Cereb Blood Flow Metab 1997, 17:597-604.
45. Loddick SA, Wong ML, Bongiorno PB, Gold PW, Licinio J, Rothwell NJ. Endogenous interleukin-1 receptor antagonist is neuroprotective. Biochem Biophys Res Commun 1997, 234:211-215. 10.1006/bbrc.1997.6436, 9168991.
46. Josephs MD, Solorzano CC, Taylor M, Rosenberg JJ, Topping D, Abouhamze A, Mackay SL, Hirsch E, Hirsh D, Labow M, Moldawer LL. Modulation of the acute phase response by altered expression of the IL-1 type 1 receptor or IL-1ra. Am J Physiol Regul Integr Comp Physiol 2000, 278:R824-830.
47. Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Gibson RM, Rothwell NJ. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 2003, 23:6470-6474.
48. Rothwell NJ, del Zoppo GJ. Editorial comment to Barone et al. Stroke 1998, 29:1950-1951.
49. Sims JE, Giri JG, Dower SK. The two interleukin-1 receptors play different roles in IL-1 actions. Clin Immunol Immunopathol 1994, 72:9-14. 10.1006/clin.1994.1100, 8020198.
50. Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Activation of the nuclear factor-kappaB is a key event in brain tolerance. J Neurosci 2001, 21:4668-4677.
51. Ohtsuki T, Ruetzler CA, Tasaki K, Hallenbeck JM. Interleukin-1 mediates induction of tolerance to global ischemia in gerbil hippocampal CA1 neurons. J Cereb Blood Flow Metab 1996, 16:1137-1142.